Live from DDW 2025 - MicroSigX Unveils M3CRC Data with Global Implications
(San Diego, 4 May 2025) Today at Digestive Disease Week (DDW) 2025, MicroSigX unveiled pivotal clinical data from its multi-center study across nine centers in the Asia-Pacific region on M3CRC, a microbiome-based diagnostic panel for colorectal cancer screening.
Presented by Dr. Louis Ho Shing Lau of CUHK Medicine, the early results from the Hong Kong, Japan, and Singapore cohorts demonstrated that M3CRC significantly outperforms FIT in detecting advanced neoplasia, particularly in asymptomatic individuals.
“M3CRC showed higher sensitivity than FIT in detecting colorectal advanced neoplasia, especially for smaller or proximal lesions,” said Dr. Lau during his presentation of the study’s interim findings.
“This milestone brings us closer to realizing the full clinical potential of M3CRC,” said Rachel Fan, CEO of MicroSigX. “It reflects our dedication to advancing microbiome science into impactful diagnostic solutions.”
With strong early data and momentum building across the region, MicroSigX is advancing toward a future where microbiome science powers earlier, more accurate, and more accessible cancer detection worldwide.
More updates to come as DDW 2025 continues.
#DDW2025
#MicroSigX
#M3CRC
#ColorectalCancer
#CancerScreening
#ClinicalData
#DiagnosticsInnovation
#MicrobiomeDiagnostics
GenieBiome Limited 精進微生物科技有限公司
Microbiota I-Center (MagIC) (香港微生物菌群創新中心)
CUHK Medicine
